{"slug": "novo-nordisk-partners-with-anthropic-to-accelerate-drug-discovery", "title": "Novo Nordisk partners with Anthropic to accelerate drug discovery", "summary": "Novo, the Danish pharmaceutical company formerly known as Novo Nordisk, announced a strategic partnership with Anthropic on September 16 to deploy Anthropic's Claude models and the Claude Science workbench in its drug discovery and development pipeline. Novo CEO Mike Doustdar said the partnership \"will supercharge our R&D organization,\" while Anthropic CEO Dario Amodei said AI could \"compress a century's worth of breakthroughs into a decade\"; financial terms were not disclosed. The deal adds Anthropic to Novo's existing AI collaborations with OpenAI and Amazon Web Services, as the maker of Ozempic and Wegovy faces competition from Eli Lilly's tirzepatide and a wave of next-generation obesity drugs.", "body_md": "Photo: Tima Miroshnichenko / Pexels\n\n# Novo Nordisk partners with Anthropic to accelerate drug discovery\n\nThe maker of Ozempic and Wegovy is betting on Anthropic's Claude models to compress decades of pharmaceutical research into years\n\nNovo, the pharmaceutical giant formerly known as Novo Nordisk, has signed a strategic partnership with AI company Anthropic to speed up its drug discovery and development pipeline. The collaboration, announced on September 16, will put Anthropic’s Claude models and the Claude Science workbench directly into the hands of Novo’s research scientists.\n\nThe deal is the latest in a series of AI bets by the Danish drugmaker, which has stated its ambition to become the world’s most AI-driven healthcare company.\n\n## What the partnership actually looks like\n\nThe initial phase of the collaboration will focus on piloting Claude Science in targeted drug discovery workflows. Novo’s scientists will identify particular R&D challenges, then deploy Anthropic’s tools against them. The company made a point of emphasizing that data governance and human oversight remain central to the process.\n\n“This partnership will supercharge our R&D organization,” said Novo CEO Mike Doustdar.\n\nAnthropic CEO Dario Amodei offered an even more ambitious framing, suggesting AI could “compress a century’s worth of breakthroughs into a decade.”\n\nFinancial terms of the partnership were not disclosed.\n\n### AI, tech, and the markets they move—in one daily briefing.\n\nDaily. Free. Join 34,000+ readers across crypto, finance, and policy.\n\n## Why Novo is going all-in on AI\n\nThis isn’t Novo’s first dance with artificial intelligence. The company has existing collaborations with both OpenAI and Amazon Web Services, suggesting a deliberate strategy of working with multiple AI providers rather than locking into a single ecosystem.\n\nOne of its most concrete AI wins so far is a tool called NovoScribe, which reduced the time required to generate clinical study reports from months to minutes.\n\nThe broader context here is competitive pressure. Novo’s blockbuster semaglutide franchise, which includes Ozempic for diabetes and Wegovy for weight loss, faces an increasingly crowded market. [Eli Lilly](https://cryptobriefing.com/markets/eli-lilly/)’s tirzepatide has proven a formidable rival, and a wave of next-generation obesity drugs from multiple competitors is advancing through clinical trials.\n\nNovo rebranded from Novo Nordisk to simply Novo earlier this year, signaling a desire to be seen as more than just an insulin and GLP-1 company.\n\n## The bigger picture for pharma and AI\n\nThe traditional drug development timeline runs roughly 10 to 15 years from initial discovery to market approval, with costs frequently exceeding a billion dollars per successful drug. Early-stage AI applications include identifying drug targets, predicting molecular interactions, and screening compound libraries. Later-stage uses involve optimizing clinical trial design and, as NovoScribe demonstrates, automating regulatory documentation.\n\n**Disclosure:** This article was edited by Editorial Team. For more information on how we create and review content, see our\n\n[Editorial Policy](https://cryptobriefing.com/editorial-policy/).", "url": "https://wpnews.pro/news/novo-nordisk-partners-with-anthropic-to-accelerate-drug-discovery", "canonical_source": "https://cryptobriefing.com/novo-nordisk-anthropic-drug-discovery/", "published_at": "2026-09-17 12:49:50+00:00", "updated_at": "2026-09-17 12:54:10.078542+00:00", "lang": "en", "topics": ["artificial-intelligence", "ai-products", "ai-startups"], "entities": ["Novo", "Anthropic", "Claude", "Claude Science", "Mike Doustdar", "Dario Amodei", "OpenAI", "Amazon Web Services"], "alternates": {"html": "https://wpnews.pro/news/novo-nordisk-partners-with-anthropic-to-accelerate-drug-discovery", "markdown": "https://wpnews.pro/news/novo-nordisk-partners-with-anthropic-to-accelerate-drug-discovery.md", "text": "https://wpnews.pro/news/novo-nordisk-partners-with-anthropic-to-accelerate-drug-discovery.txt", "jsonld": "https://wpnews.pro/news/novo-nordisk-partners-with-anthropic-to-accelerate-drug-discovery.jsonld"}}